Table 2.1: Incidence of ischemic stroke in the seven major markets, 2002 41
Table 2.2: Antithrombotics in development for acute ischemic stroke, 2003 49
Table 3.3: Prevalence of Alzheimer’s disease across the seven major markets, 2002 59
Table 3.4: Leading and new Alzheimer’s disease product sales, 2001-08 63
Table 3.5: Late stage Alzheimer’s disease pipeline, 2003 74
Table 4.6: Leading and new arthritis product sales, 2001-08 87
Table 4.7: Late-stage arthritis pipeline, 2003 96
Table 5.8: Prevalence of diabetes in the seven major markets, 2002 106
Table 5.9: Leading and new diabetes product sales, 2001-08 112
Table 5.10: Non-invasive insulin pipeline, 2003 120
Table 6.11: Prevalence of male sexual dysfunction, 2002 (000s) 133
Table 6.12: Prevalence of complete and severe erectile dysfunction in the over 40s, 2002 (000s) 135
Table 6.13: Global forecasts of leading and innovative erectile dysfunction drugs to 2008 137
Table 6.14: Male sexual dysfunction pipeline, phase II and above, 2003 145
Table 7.15: Prevalence of osteopenia and osteoporosis in the post-menopausal population across the seven major markets, 2002 157
Table 7.16: Prevalence of osteopenia and osteoporosis in men aged 50+, 2002 160
Table 7.17: Leading and new product sales in the osteoporosis market, 2002-08 165
Table 7.18: Osteoporosis pipeline, phase II and above, 2003 178
Table 8.19: Prevalence of prostate cancer in the seven major markets, 2003 191
Table 8.20: Leading prostate cancer product sales, 2001-08 193
Table 8.21: Late-stage prostate cancer pipeline, 2003
Table 2.1: Incidence of ischemic stroke in the seven major markets, 2002 41
Table 2.2: Antithrombotics in development for acute ischemic stroke, 2003 49
Table 3.3: Prevalence of Alzheimer’s disease across the seven major markets, 2002 59
Table 3.4: Leading and new Alzheimer’s disease product sales, 2001-08 63
Table 3.5: Late stage Alzheimer’s disease pipeline, 2003 74
Table 4.6: Leading and new arthritis product sales, 2001-08 87
Table 4.7: Late-stage arthritis pipeline, 2003 96
Table 5.8: Prevalence of diabetes in the seven major markets, 2002 106
Table 5.9: Leading and new diabetes product sales, 2001-08 112
Table 5.10: Non-invasive insulin pipeline, 2003 120
Table 6.11: Prevalence of male sexual dysfunction, 2002 (000s) 133
Table 6.12: Prevalence of complete and severe erectile dysfunction in the over 40s, 2002 (000s) 135
Table 6.13: Global forecasts of leading and innovative erectile dysfunction drugs to 2008 137
Table 6.14: Male sexual dysfunction pipeline, phase II and above, 2003 145
Table 7.15: Prevalence of osteopenia and osteoporosis in the post-menopausal population across the seven major markets, 2002 157
Table 7.16: Prevalence of osteopenia and osteoporosis in men aged 50+, 2002 160
Table 7.17: Leading and new product sales in the osteoporosis market, 2002-08 165
Table 7.18: Osteoporosis pipeline, phase II and above, 2003 178
Table 8.19: Prevalence of prostate cancer in the seven major markets, 2003 191
Table 8.20: Leading prostate cancer product sales, 2001-08 193
Table 8.21: Late-stage prostate cancer pipeline, 2003
[Tabellenverzeichnis ausblenden]
